May 2006
Volume 47, Issue 13
ARVO Annual Meeting Abstract  |   May 2006
Aqueous PGE2 Inhibition of Ketorolac 0.4% vs. Nepafenac 0.1% in Patients Undergoing Phacoemulsification
Author Affiliations & Notes
  • L.M. Amico
    Bucci Laser Vision Institute, Wilkes Barre, PA
  • F.A. Bucci, Jr.
    Bucci Laser Vision Institute, Wilkes Barre, PA
  • D. Waterbury
    Consultant, San Carlos, CA
  • Footnotes
    Commercial Relationships  L.M. Amico, Allergan, R; F.A. Bucci, Allergan, Inc., R; D. Waterbury, Allergan, Inc., C.
  • Footnotes
    Support  Grant
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 2602. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L.M. Amico, F.A. Bucci, Jr., D. Waterbury; Aqueous PGE2 Inhibition of Ketorolac 0.4% vs. Nepafenac 0.1% in Patients Undergoing Phacoemulsification . Invest. Ophthalmol. Vis. Sci. 2006;47(13):2602.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To determine and evaluate the PGE2 inhibition of 2 topical NSAIDs [ketorolac tromethamine 0.4%, (Acular LS) and nepafenac 0.1% (Nevanac)] in phaco patients.

Methods: : Single center, randomized, double–masked study of 60 patients randomized to receive either ketorolac 0.4% or nepafenac 0.1% 4 times daily for 2 days preoperatively and every 10 minutes x 4 in the hour immediately prior to phacoemulsification. After completion of the paracentesis site with a superblade, aqueous humor (.15cc) was collected through the peripheral clear cornea with a 30 gage needle attached to a TB syringe. Following collection, aqueous samples were stored T –60º C prior to analysis. Aqueous humor was diluted 1:10 in buffer, and then assayed in triplicate for PGE2 by using a competitive enzyme immunoassay using a monoclonal antibody. The product of the assay enzymatic reaction was determined using a plate reader set at 405nM.

Results: : In a preliminary analysis of 53 patients (n=25 ketorolac and n=28 nepafenac), ketorlac–treated eyes were statistically significantly more likely to be below the level of detection (<100 pg/ml) than nepafenac–treated eyes [16/25 (64%) of ketorolac–treated eyes, compared with 7/28 (25%) of nepafenac eyes, (p=.004)]. In the remaining samples, the mean PGE2 value in the ketorolac–treated eyes (n=9) was 305 ± 155.2 pg/ml and 385 ± 173.3 pg/ml in the nepafenac–treated eyes (n = 21) (p=.198).

Conclusions: : The findings of this preliminary analysis suggests that ketorolac 0.4% may inhibit aqueous PGE2 to a greater extent than nepafenac 0.1% post phacoemulsification . Further analysis will be performed to confirm these findings.

Keywords: inflammation 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.